Global Phage Display-based Antibody Discovery Platform 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI02261173

Publication Date:

February 21, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

IT Services [2]

Software [3]

Computing & Electronics [4]

Description:

The global Phage Display-based Antibody Discovery Platform market size is predicted to grow from US$ 925 million in 2025 to US$ 1322 million in 2031; it is expected to grow at a CAGR of 6.1% from 2025 to 2031.
Phage display is a technique that allows the selection of antibodies, or antibody fragments, with a specific binding affinity for a target antigen. Bacteriophages (viruses that infect bacteria) are engineered to display a library of antibody fragments on their surface then mixed with an immobilized target antigen. The phages that bind to the antigen are isolated and amplified. The process is repeated multiple times to isolate the phage that displays the highest binding affinity to the target antigen. Once the phage with the desired antibody fragment is identified, the DNA sequence encoding the fragment can be extracted and used to produce large quantities. The antibody fragments are derived from a library of light and heavy chains with minor or major alterations that are hypothesized to impact binding efficiency and/or specificity.Phage display is a versatile and powerful method for generating antibodies with high specificity, affinity and functionality.
United States market for Phage Display-based Antibody Discovery Platform is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Phage Display-based Antibody Discovery Platform is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Phage Display-based Antibody Discovery Platform is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Phage Display-based Antibody Discovery Platform players cover Creative Biolabs, DH Life Sciences, LLC, Bio-Rad Laboratories, Inc, ProteoGenix, Charles River Laboratories, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淧hage Display-based Antibody Discovery Platform Industry Forecast鈥� looks at past sales and reviews total world Phage Display-based Antibody Discovery Platform sales in 2024, providing a comprehensive analysis by region and market sector of projected Phage Display-based Antibody Discovery Platform sales for 2025 through 2031. With Phage Display-based Antibody Discovery Platform sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Phage Display-based Antibody Discovery Platform industry.
This Insight Report provides a comprehensive analysis of the global Phage Display-based Antibody Discovery Platform landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Phage Display-based Antibody Discovery Platform portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Phage Display-based Antibody Discovery Platform market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Phage Display-based Antibody Discovery Platform and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Phage Display-based Antibody Discovery Platform.
This report presents a comprehensive overview, market shares, and growth opportunities of Phage Display-based Antibody Discovery Platform market by product type, application, key players and key regions and countries.
Segmentation by Type:
T4 Phage
T7 Phage
位 Phage
Filamentous Phage
Segmentation by Application:
Basic Research
Clinical Diagnosis
Biologics Development
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Creative Biolabs
DH Life Sciences, LLC
Bio-Rad Laboratories, Inc
ProteoGenix
Charles River Laboratories
Sino Biological, Inc.
Adagene
ImmunoPrecise Antibodies Ltd.
Specifica Inc.
Pharmaron

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Phage Display-based Antibody Discovery Platform 麻豆原创 Size (2020-2031)
2.1.2 Phage Display-based Antibody Discovery Platform 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Phage Display-based Antibody Discovery Platform by Country/Region (2020, 2024 & 2031)
2.2 Phage Display-based Antibody Discovery Platform Segment by Type
2.2.1 T4 Phage
2.2.2 T7 Phage
2.2.3 位 Phage
2.2.4 Filamentous Phage
2.3 Phage Display-based Antibody Discovery Platform 麻豆原创 Size by Type
2.3.1 Phage Display-based Antibody Discovery Platform 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Phage Display-based Antibody Discovery Platform 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Phage Display-based Antibody Discovery Platform Segment by Application
2.4.1 Basic Research
2.4.2 Clinical Diagnosis
2.4.3 Biologics Development
2.5 Phage Display-based Antibody Discovery Platform 麻豆原创 Size by Application
2.5.1 Phage Display-based Antibody Discovery Platform 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Phage Display-based Antibody Discovery Platform 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Phage Display-based Antibody Discovery Platform 麻豆原创 Size by Player
3.1 Phage Display-based Antibody Discovery Platform 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Phage Display-based Antibody Discovery Platform Revenue by Player (2020-2025)
3.1.2 Global Phage Display-based Antibody Discovery Platform Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Phage Display-based Antibody Discovery Platform Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Phage Display-based Antibody Discovery Platform by Region
4.1 Phage Display-based Antibody Discovery Platform 麻豆原创 Size by Region (2020-2025)
4.2 Global Phage Display-based Antibody Discovery Platform Annual Revenue by Country/Region (2020-2025)
4.3 Americas Phage Display-based Antibody Discovery Platform 麻豆原创 Size Growth (2020-2025)
4.4 APAC Phage Display-based Antibody Discovery Platform 麻豆原创 Size Growth (2020-2025)
4.5 Europe Phage Display-based Antibody Discovery Platform 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Phage Display-based Antibody Discovery Platform 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Phage Display-based Antibody Discovery Platform 麻豆原创 Size by Country (2020-2025)
5.2 Americas Phage Display-based Antibody Discovery Platform 麻豆原创 Size by Type (2020-2025)
5.3 Americas Phage Display-based Antibody Discovery Platform 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Phage Display-based Antibody Discovery Platform 麻豆原创 Size by Region (2020-2025)
6.2 APAC Phage Display-based Antibody Discovery Platform 麻豆原创 Size by Type (2020-2025)
6.3 APAC Phage Display-based Antibody Discovery Platform 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Phage Display-based Antibody Discovery Platform 麻豆原创 Size by Country (2020-2025)
7.2 Europe Phage Display-based Antibody Discovery Platform 麻豆原创 Size by Type (2020-2025)
7.3 Europe Phage Display-based Antibody Discovery Platform 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Phage Display-based Antibody Discovery Platform by Region (2020-2025)
8.2 Middle East & Africa Phage Display-based Antibody Discovery Platform 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Phage Display-based Antibody Discovery Platform 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Phage Display-based Antibody Discovery Platform 麻豆原创 Forecast
10.1 Global Phage Display-based Antibody Discovery Platform Forecast by Region (2026-2031)
10.1.1 Global Phage Display-based Antibody Discovery Platform Forecast by Region (2026-2031)
10.1.2 Americas Phage Display-based Antibody Discovery Platform Forecast
10.1.3 APAC Phage Display-based Antibody Discovery Platform Forecast
10.1.4 Europe Phage Display-based Antibody Discovery Platform Forecast
10.1.5 Middle East & Africa Phage Display-based Antibody Discovery Platform Forecast
10.2 Americas Phage Display-based Antibody Discovery Platform Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Phage Display-based Antibody Discovery Platform Forecast
10.2.2 Canada 麻豆原创 Phage Display-based Antibody Discovery Platform Forecast
10.2.3 Mexico 麻豆原创 Phage Display-based Antibody Discovery Platform Forecast
10.2.4 Brazil 麻豆原创 Phage Display-based Antibody Discovery Platform Forecast
10.3 APAC Phage Display-based Antibody Discovery Platform Forecast by Region (2026-2031)
10.3.1 China Phage Display-based Antibody Discovery Platform 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Phage Display-based Antibody Discovery Platform Forecast
10.3.3 Korea 麻豆原创 Phage Display-based Antibody Discovery Platform Forecast
10.3.4 Southeast Asia 麻豆原创 Phage Display-based Antibody Discovery Platform Forecast
10.3.5 India 麻豆原创 Phage Display-based Antibody Discovery Platform Forecast
10.3.6 Australia 麻豆原创 Phage Display-based Antibody Discovery Platform Forecast
10.4 Europe Phage Display-based Antibody Discovery Platform Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Phage Display-based Antibody Discovery Platform Forecast
10.4.2 France 麻豆原创 Phage Display-based Antibody Discovery Platform Forecast
10.4.3 UK 麻豆原创 Phage Display-based Antibody Discovery Platform Forecast
10.4.4 Italy 麻豆原创 Phage Display-based Antibody Discovery Platform Forecast
10.4.5 Russia 麻豆原创 Phage Display-based Antibody Discovery Platform Forecast
10.5 Middle East & Africa Phage Display-based Antibody Discovery Platform Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Phage Display-based Antibody Discovery Platform Forecast
10.5.2 South Africa 麻豆原创 Phage Display-based Antibody Discovery Platform Forecast
10.5.3 Israel 麻豆原创 Phage Display-based Antibody Discovery Platform Forecast
10.5.4 Turkey 麻豆原创 Phage Display-based Antibody Discovery Platform Forecast
10.6 Global Phage Display-based Antibody Discovery Platform Forecast by Type (2026-2031)
10.7 Global Phage Display-based Antibody Discovery Platform Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Phage Display-based Antibody Discovery Platform Forecast
11 Key Players Analysis
11.1 Creative Biolabs
11.1.1 Creative Biolabs Company Information
11.1.2 Creative Biolabs Phage Display-based Antibody Discovery Platform Product Offered
11.1.3 Creative Biolabs Phage Display-based Antibody Discovery Platform Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Creative Biolabs Main Business Overview
11.1.5 Creative Biolabs Latest Developments
11.2 DH Life Sciences, LLC
11.2.1 DH Life Sciences, LLC Company Information
11.2.2 DH Life Sciences, LLC Phage Display-based Antibody Discovery Platform Product Offered
11.2.3 DH Life Sciences, LLC Phage Display-based Antibody Discovery Platform Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 DH Life Sciences, LLC Main Business Overview
11.2.5 DH Life Sciences, LLC Latest Developments
11.3 Bio-Rad Laboratories, Inc
11.3.1 Bio-Rad Laboratories, Inc Company Information
11.3.2 Bio-Rad Laboratories, Inc Phage Display-based Antibody Discovery Platform Product Offered
11.3.3 Bio-Rad Laboratories, Inc Phage Display-based Antibody Discovery Platform Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Bio-Rad Laboratories, Inc Main Business Overview
11.3.5 Bio-Rad Laboratories, Inc Latest Developments
11.4 ProteoGenix
11.4.1 ProteoGenix Company Information
11.4.2 ProteoGenix Phage Display-based Antibody Discovery Platform Product Offered
11.4.3 ProteoGenix Phage Display-based Antibody Discovery Platform Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 ProteoGenix Main Business Overview
11.4.5 ProteoGenix Latest Developments
11.5 Charles River Laboratories
11.5.1 Charles River Laboratories Company Information
11.5.2 Charles River Laboratories Phage Display-based Antibody Discovery Platform Product Offered
11.5.3 Charles River Laboratories Phage Display-based Antibody Discovery Platform Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Charles River Laboratories Main Business Overview
11.5.5 Charles River Laboratories Latest Developments
11.6 Sino Biological, Inc.
11.6.1 Sino Biological, Inc. Company Information
11.6.2 Sino Biological, Inc. Phage Display-based Antibody Discovery Platform Product Offered
11.6.3 Sino Biological, Inc. Phage Display-based Antibody Discovery Platform Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Sino Biological, Inc. Main Business Overview
11.6.5 Sino Biological, Inc. Latest Developments
11.7 Adagene
11.7.1 Adagene Company Information
11.7.2 Adagene Phage Display-based Antibody Discovery Platform Product Offered
11.7.3 Adagene Phage Display-based Antibody Discovery Platform Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Adagene Main Business Overview
11.7.5 Adagene Latest Developments
11.8 ImmunoPrecise Antibodies Ltd.
11.8.1 ImmunoPrecise Antibodies Ltd. Company Information
11.8.2 ImmunoPrecise Antibodies Ltd. Phage Display-based Antibody Discovery Platform Product Offered
11.8.3 ImmunoPrecise Antibodies Ltd. Phage Display-based Antibody Discovery Platform Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 ImmunoPrecise Antibodies Ltd. Main Business Overview
11.8.5 ImmunoPrecise Antibodies Ltd. Latest Developments
11.9 Specifica Inc.
11.9.1 Specifica Inc. Company Information
11.9.2 Specifica Inc. Phage Display-based Antibody Discovery Platform Product Offered
11.9.3 Specifica Inc. Phage Display-based Antibody Discovery Platform Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Specifica Inc. Main Business Overview
11.9.5 Specifica Inc. Latest Developments
11.10 Pharmaron
11.10.1 Pharmaron Company Information
11.10.2 Pharmaron Phage Display-based Antibody Discovery Platform Product Offered
11.10.3 Pharmaron Phage Display-based Antibody Discovery Platform Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Pharmaron Main Business Overview
11.10.5 Pharmaron Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.